Insights
Search Results
Client Highlights
6.02.26
Wilson Sonsini Advises BVF Partners on IP Matters Related to Contraline’s $92.5 Million Series B
On June 2, 2026, Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. Wilson Sonsini Goodrich & Rosati advised BVF Partners on IP matters related to the transaction.
Client Highlights
6.01.26
Wilson Sonsini Advises Oak Hill Bio on Patent Matters Related to $32.5 Million Series A Financing
On June 1, 2026, Oak Hill Bio, a clinical-stage rare disease therapeutics company, announced the closing of a $32.5 million Series A financing. The round was co-led by Balyasny Asset Management, venBio, and Janus Henderson Investors, with participation from KCap Biotechnology Fund. Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on patent matters related to the transaction.
News Articles
6.01.26
Wilson Sonsini Joins Nucleate Leadership Council as Co-Founding Member
On June 1, 2026, Nucleate, a nonprofit organization dedicated to empowering the next generation of biotech leaders, announced the launch of the Nucleate Leadership Council (NLC), a new community of biotech leaders and disruptors committed to supporting the next generation of scientists and entrepreneurs. Wilson Sonsini is proud to join the NLC as a co-founding member.
News Articles
5.21.26
Michael Hostetler Recognized Among Daily Journal’s 2026 Top IP Lawyers
On May 21, 2026, Wilson Sonsini partner Michael Hostetler was recognized in the Daily Journal’s special report "Top Intellectual Property Lawyers 2026," an annual list honoring California's top lawyers specializing in patent litigation, trademark, and copyright. Michael has over 25 years of experience specializing in patent law for life sciences companies, particularly in pharmaceuticals and biotechnology.
Client Highlights
5.11.26
Wilson Sonsini Advises Odyssey Therapeutics on Patent Matters Related to IPO
On May 7, 2026, Odyssey Therapeutics, a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Odyssey’s common stock began trading on the Nasdaq Capital Market on May 8, 2026, under the ticker symbol “ODTX.” The offering closed on May 11, 2026. Wilson Sonsini Goodrich & Rosati advised Odyssey on patent matters related to the transaction.
Alerts
5.07.26
Federal Circuit Provides Path to Written Description and Enablement for Patents Related to Methods of Using a Well-Known Class of Molecules
On April 16, 2026, the U.S. Court of Appeals for the Federal Circuit (the court) issued a precedential decision in Teva Pharmaceuticals International GmbH v. Eli Lily and Company, determining that the claims of Teva’s U.S. Patent Nos. 8,586,045 (the ’045 patent), 9,884,907 (the ’907 patent), and 9,884,908 (the ’908 patent) (collectively, the Headache Patents) relating to methods of reducing headache by administration of humanized anti-CGRP antagonist antibodies are not invalid for lack of written description or enablement. The decision reversed a district court’s judgment as a matter of law (JMOL) decision concluding otherwise, and reinstated the jury’s findings that Eli Lilly’s Emgality® product willfully infringed the Headache Patents.
News Articles
5.07.26
Tait Graves Named Among WIPR Leaders 2026
On May 1, 2026, World Intellectual Property Review (WIPR) named Wilson Sonsini partner Charles Tait Graves to its WIPR Leaders 2026 guide, a list of the leading intellectual property attorneys globally. The guide recognizes individuals and attorneys who are leaders in their fields and shaping the future of intellectual property in the legal space.
Client Highlights
5.04.26
Firm Advises Candid Therapeutics on Patent Matters Related to Its $2 Billion Acquisition by UCB
On May 3, 2026, UCB, a global biopharmaceutical company, announced a definitive agreement to acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers. Under the terms of the agreement, UCB will pay $2 billion in upfront payments and up to $200 million in potential future milestone payments. Wilson Sonsini Goodrich & Rosati advised Candid on patent matters related to the transaction.
Client Highlights
4.16.26
Wilson Sonsini Advises Terremoto on IP Matters Related to $108 Million Series C
On April 15, 2026, Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, announced the closing of a $108 million Series C financing round. The round includes new investors RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines, and participation from existing investors OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management. Wilson Sonsini Goodrich & Rosati advised Terremoto on IP matters related to the transaction.
Client Highlights
4.02.26
Wilson Sonsini Advises Frazier Life Sciences on IP Matters Related to Immutrin’s $87 Million Series A
On March 24, 2026, Immutrin, a biotechnology company developing next generation antibody therapy to reverse amyloidosis, announced it has successfully raised $87 million in a Series A financing. The round was led by new investor Frazier Life Sciences, with participation from F-Prime, Qiming Venture Partners, SR One, and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures. Wilson Sonsini Goodrich & Rosati advised Frazier Life Sciences on patent matters related to the transaction.